To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Virion was recently awarded a ...
PHILADELPHIA, February 22, 2026--Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at ...
PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and Ocean Biomedical, Inc. (NASDAQ: OCEA), a ...
PHILADELPHIA, PA — Virion Therapeutics LLC reported data showing its experimental hepatitis B immunotherapy VRON-0200 generated sustained immune responses in chronically infected patients following a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Both Virion Therapeutics and ...
PHILADELPHIA, Oct. 26, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean ...
Membrane proteins are key targets for therapeutic intervention using antibody biologics. Over 60% of FDA-approved drugs act on these proteins. Studying them is challenging because the proteins must be ...
Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026 Virion ...
PHILADELPHIA--(BUSINESS WIRE)--Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results